Lindsey Rolfe
Director/Board Member presso ATRECA, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Lindsey Rolfe is an Independent Director at Atreca, Inc. and CERo Therapeutics Holdings, Inc. They are also a Member at The Royal College of Physicians.
Previously, Dr. Rolfe worked as the Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc. Dr. Rolfe holds a doctorate degree from The University of Edinburgh.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
-.--% | 05/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Lindsey Rolfe
Società | Posizione | Inizio |
---|---|---|
ATRECA, INC. | Director/Board Member | 22/08/2019 |
The Royal College of Physicians | Corporate Officer/Principal | - |
Precedenti posizioni note di Lindsey Rolfe
Società | Posizione | Fine |
---|---|---|
CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/06/2023 |
Formazione di Lindsey Rolfe
The University of Edinburgh | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ATRECA, INC. | Health Technology |
Aziende private | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Lindsey Rolfe